Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer

BACKGROUND: ADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T cells (ADP-A2M10) are genetically engineered autologous T cells that express a high-affinity melanoma-associated antigen A10 (MAGE-A10)-specific T-cell receptor (TCR) targeting MAGE-A10(+) tumors in the context of human leuk...

Descripción completa

Detalles Bibliográficos
Autores principales: Blumenschein, George R, Devarakonda, Siddhartha, Johnson, Melissa, Moreno, Victor, Gainor, Justin, Edelman, Martin J, Heymach, John V, Govindan, Ramaswamy, Bachier, Carlos, Doger de Spéville, Bernard, Frigault, Matthew J, Olszanski, Anthony J, Lam, Vincent K, Hyland, Natalie, Navenot, Jean-Marc, Fayngerts, Svetlana, Wolchinsky, Zohar, Broad, Robyn, Batrakou, Dzmitry, Pentony, Melissa M, Sanderson, Joseph P, Gerry, Andrew, Marks, Diane, Bai, Jane, Holdich, Tom, Norry, Elliot, Fracasso, Paula M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796260/
https://www.ncbi.nlm.nih.gov/pubmed/35086946
http://dx.doi.org/10.1136/jitc-2021-003581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796260/
https://www.ncbi.nlm.nih.gov/pubmed/35086946
http://dx.doi.org/10.1136/jitc-2021-003581

Ejemplares similares